Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2013 | Original Article

Somatostatin receptor PET in neuroendocrine tumours: ⁶⁸Ga-DOTA⁰,Tyr³-octreotide versus ⁶⁸Ga-DOTA⁰-lanreotide

Authors: Daniel Putzer, Alexander Kroiss, Dietmar Waitz, Michael Gabriel, Tatjana Traub-Weidinger, Christian Uprimny, Elisabeth von Guggenberg, Clemens Decristoforo, Boris Warwitz, Gerlig Widmann, Irene Johanna Virgolini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2013

Abstract

Purpose

The aim of this study was to evaluate the impact of ⁶⁸Ga-labelled DOTA⁰-lanreotide (⁶⁸Ga-DOTA-LAN) on the diagnostic assessment of neuroendocrine tumour (NET) patients with low to moderate uptake on planar somatostatin receptor (SSTR) scintigraphy or ⁶⁸Ga-labelled DOTA⁰,Tyr³-octreotide (⁶⁸Ga-DOTA-TOC) positron emission tomography (PET).

Methods

Fifty-three patients with histologically confirmed NET and clinical signs of progressive disease, who had not qualified for peptide receptor radionuclide therapy (PRRT) on planar SSTR scintigraphy or ⁶⁸Ga-DOTA-TOC PET (n = 38) due to lack of tracer uptake, underwent ⁶⁸Ga-DOTA-LAN PET to evaluate a treatment option with ⁹⁰Y-labelled lanreotide according to the MAURITIUS trial. The included patients received 150 ± 30 MBq of each radiopharmaceutical intravenously. PET scans were acquired 60–90 min after intravenous bolus injection. Image results from both PET scans were compared head to head, focusing on the intensity of tracer uptake in terms of treatment decision. CT was used for morphologic correlation of tumour lesions. To further evaluate the binding affinities of each tracer, quantitative and qualitative values were calculated for target lesions.

Results

⁶⁸Ga-DOTA-LAN and ⁶⁸Ga-DOTA-TOC both showed equivalent findings in 24/38 patients when fused PET/CT images were interpreted. The sensitivity, specificity and accuracy of ⁶⁸Ga-DOTA-LAN in comparison to CT were 0.63, 0.5 and 0.62 (n = 53; p < 0.0001) and for ⁶⁸Ga-DOTA-TOC in comparison to CT 0.78, 0.5 and 0.76 (n = 38; p < 0.013), respectively. ⁶⁸Ga-DOTA-TOC showed a significantly higher maximum standardized uptake value (SUV_max) regarding the primary tumour in 25 patients (p < 0.003) and regarding the liver in 30 patients (p < 0.009) compared to ⁶⁸Ga-DOTA-LAN. Corresponding values of both PET scans for tumour and liver did not show any significant correlation. ⁶⁸Ga-DOTA-TOC revealed more tumour sites than ⁶⁸Ga-DOTA-LAN (106 vs 53). The tumour to background ratios for tumour and liver calculated from SUV_max measurements were significantly higher for ⁶⁸Ga-DOTA-TOC than ⁶⁸Ga-DOTA-LAN (p < 0.02).

Conclusion

⁶⁸Ga-DOTA-TOC PET imaging is an established imaging procedure for accurate staging of NET patients. ⁶⁸Ga-DOTA-LAN should only be considered as a PET tracer of second choice in patients with no pathologic tracer uptake on ⁶⁸Ga-DOTA-TOC PET. In these patients, ⁶⁸Ga-DOTA-LAN PET can provide valuable information when evaluating PRRT as the treatment option, as a broader spectrum of human SSTR subtypes can be detected.

Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011;18:127–37.PubMed

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.PubMedCrossRef

Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002;66:161–83.PubMedCrossRef

Reubi JC. Clinical relevance of somatostatin receptor imaging. Eur J Endocrinol 1994;131:575–6.PubMedCrossRef

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53–73.PubMedCrossRef

Öberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742–53.PubMedCrossRef

Virgolini IJ, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928–36.PubMed

Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010;54:3–15.PubMed

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31.PubMedCrossRef

10.

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47.PubMedCrossRef

11.

Kaltsas GA, Papadogias G, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005;12:683–99.PubMedCrossRef

12.

Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50–8.PubMed

13.

Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010;54:92–9.PubMed

14.

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRef

15.

Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214–21.PubMedCrossRef

16.

Gabriel M, Oberbauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427–34.PubMedCrossRef

17.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.PubMedCrossRef

18.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617–26.PubMedCrossRef

19.

Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136–48.PubMedCrossRef

20.

Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144–51.PubMedCrossRef

21.

Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006;33:532–40.PubMedCrossRef

22.

Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, et al. New trends in peptide receptor ligands. Q J Nucl Med 2001;45:153–9.PubMed

23.

Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine’s view. J Pharm Pharm Sci 2007;10:321s–37s.PubMed

24.

Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, et al. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging 2010;54:52–60.PubMed

25.

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. 111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148–55.PubMedCrossRef

26.

Breeman WA, de Jong M, de Blois E, Bernard BT, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478–85.PubMedCrossRef

27.

Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010;16:2963–70.PubMedCrossRef

28.

Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun 2004;25:445–9.PubMedCrossRef

29.

Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, et al. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998;39:2090–4.PubMed

30.

Traub T, Petkov V, Ofluoglu S, Pangert T, Raderer M, Fueger BJ, et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001;42:1309–15.PubMed

31.

Kwekkeboom DJ, de Herder W, van Ejick CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40:78–88.PubMedCrossRef

32.

Moncayo R. Reflections on the theory of “silver bullet” octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis. EJNMMI Res 2011;1:9.PubMedCrossRef

33.

Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med 2001;42:1856–62.PubMed

Title: Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide
Authors: Daniel Putzer
Alexander Kroiss
Dietmar Waitz
Michael Gabriel
Tatjana Traub-Weidinger
Christian Uprimny
Elisabeth von Guggenberg
Clemens Decristoforo
Boris Warwitz
Gerlig Widmann
Irene Johanna Virgolini
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2286-6

2024 ASCO Annual Meeting

Springer Medicine

Somatostatin receptor PET in neuroendocrine tumours: ⁶⁸Ga-DOTA⁰,Tyr³-octreotide versus ⁶⁸Ga-DOTA⁰-lanreotide

Abstract

Purpose

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2013

FDG PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach

Exercise training early after acute myocardial infarction reduces stress-induced hypoperfusion and improves left ventricular function

Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis

Interrelation between myocardial oxidative metabolism and diastolic function in patients undergoing surgical ventricular reconstruction

The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis

Temporal evolution of administered activity in cardiac gated SPECT and patients’ effective dose: analysis of an historical series